Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin&rsquo;s gastric lymphoma patients

doi:10.3748/wjg.v12.i12.1924

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 12

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2623)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-7) series.

Item

Count

PDF

287

HTML

2062

Figures (1-5)

144

Tables (1-7)

130

Sum=2623

Mar 28, 2006 (publication date) through Apr 30, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Mar 28, 2006; 12(12): 1924-1932
Published online Mar 28, 2006. doi: 10.3748/wjg.v12.i12.1924

Table 4 ICAM-3, PECAM-1 and HLA-DR antigen expressions in gastric lymphoma tumor cells ¹

Gene expression	Frequency	Percentage(%)
ICAM-3(+)/PECAM-1(+)/HLA-DR tumor(+)	4	11.1
ICAM-3(+)/PECAM-1(+)/HLA-DR tumor(-)	1	2.8
ICAM-3(+)/PECAM-1(-)/HLA-DR tumor(-)	4	11.1
ICAM-3(+)/PECAM-1(-)/HLA-DR tumor(+)	8	22.2
ICAM-3(-)/PECAM-1(+)/HLA-DR tumor(+)	4	11.1
ICAM-3(-)/PECAM-1(+)/HLA-DR tumor(-)	1	2.8
ICAM-3(-)/PECAM-1(-)/HLA-DR tumor(+)	10	27.8
ICAM-3(-)/PECAM-1(-)/HLA-DR tumor(-)	4	11.1

¹While PECAM-1 and ICAM-3 were positive when more than 5% of the tumor cells were stained positive, HLA-DR antigen positivity depicted in Table 4 represents the 15% cut-off level used in our survival analysis.

Citation: Darom A, Gomatos IP, Leandros E, Chatzigianni E, Panousopoulos D, Konstadoulakis MM, Androulakis G. Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin’s gastric lymphoma patients. World J Gastroenterol 2006; 12(12): 1924-1932
URL: https://www.wjgnet.com/1007-9327/full/v12/i12/1924.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i12.1924